ArticleBMC oral health2025
Development and validation of nomograms for ameloblastoma recurrence prediction: a multinational, two-center study from Seoul, South Korea and Wuhan, China.
Article in BMC oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveThis study aimed to construct and validate region-specific nomograms to predict ameloblastoma recurrence and to investigate potential geographic differences in recurrence-related risk factors between South Korea and China. MATERIALS AND
methodsA total of 816 patients with ameloblastoma treated between 2006 and 2023 were retrospectively analyzed from Yonsei University Dental Hospital (n = 372) and Hospital of Stomatology, Wuhan University (n = 444). Demographic, radiographic, and pathological variables were collected. Logistic regression analysis identified recurrence-associated predictors. Separate nomograms were developed and internally validated for each cohort. Model performance was evaluated using the area under the curve (AUC), calibration curves, and decision curve analysis.
resultsThe South Korean nomogram incorporated six variables, including pathological type, malignant transformation, surgical method, imaging type, tumor size, and cortical bone destruction (AUC = 0.757). The Chinese model incorporated eight predictors, including sex, root resorption, and number of involved teeth (AUC = 0.787). Calibration and decision curves indicated strong agreement between predicted and observed outcomes and favorable clinical applicability.
conclusionsBoth nomograms demonstrated good predictive accuracy and highlighted regional differences in risk factors. These findings support the integration of multicenter data to enhance recurrence prediction in ameloblastoma. CLINICAL RELEVANCE: The developed tools can guide individualized treatment planning and long-term follow-up, aiding clinicians in early identification of high-risk patients and optimizing surgical strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.